Aims and scope

Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing.

Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis.

The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice.

Key topics covered include:

• Risk factors, prevention and sun safety education
• Diagnosis, staging and grading
• Surgical excision of melanoma lesions
• Sentinel lymph node biopsy
• Biological therapies, including immunotherapy and vaccination
• Novel chemotherapy options
• Treatment of metastasis
• Prevention of recurrence
• Patient care and quality of life

Melanoma Management delivers an accessible overview of current and future melanoma management options in a concise format that is ideal for the busy clinician. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including COPE, ICMJE and GPP3.